activins and Anemia

activins has been researched along with Anemia in 12 studies

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (8.33)	18.7374
1990's	1 (8.33)	18.2507
2000's	0 (0.00)	29.6817
2010's	9 (75.00)	24.3611
2020's	1 (8.33)	2.80

Authors

Authors	Studies
Lan, Z; Lv, Z; Xiao, Y; Zuo, W	1
Del Vecchio, L; Locatelli, F; Luise, MC	1
Attie, KM; Chromik, J; Germing, U; Giagounidis, A; Götze, KS; Kiewe, P; Laadem, A; Mayer, K; Platzbecker, U; Radsak, M; Sherman, ML; Wolff, T; Zhang, X	1
Jelkmann, W	2
Narayanan, S	1
Fenaux, P; Kiladjian, JJ; Platzbecker, U	1
Castelli, G; Elvira, P; Testa, U	1
Bonomini, M; Del Vecchio, L; Locatelli, F; Sirolli, V	1
Camaschella, C; Nai, A	1
Kawano, Y; Kuroda, Y; Shimizu, T; Takaue, Y	1
Eto, Y; Kosaka, M; Sakai, R; Shibai, H; Shiozaki, M; Tabuchi, M	1

Reviews

9 review(s) available for activins and Anemia

Article	Year
From bench to bedside: The promise of sotatercept in hematologic disorders. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 165 Topics: Activins; Anemia; Bone Morphogenetic Proteins; Erythropoiesis; Growth Differentiation Factors; Humans; Prospective Studies; Recombinant Fusion Proteins; Transforming Growth Factor beta	2023
Current and future chemical therapies for treating anaemia in chronic kidney disease. Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:8 Topics: Activin Receptors, Type II; Activins; Anemia; Erythropoiesis; Hematinics; Humans; Hypoxia-Inducible Factor 1; Immunoglobulin Fc Fragments; Iron; Recombinant Fusion Proteins; Renal Insufficiency, Chronic; Treatment Outcome	2017
Activin receptor ligand traps in chronic kidney disease. Current opinion in nephrology and hypertension, 2018, Volume: 27, Issue:5 Topics: Activin Receptors; Activin Receptors, Type II; Activins; Anemia; Animals; Erythropoiesis; Hematinics; Humans; Immunoglobulin Fc Fragments; Ligands; Recombinant Fusion Proteins; Renal Insufficiency, Chronic; Transforming Growth Factor beta	2018
Managing anaemia in bone marrow failure syndromes. Current opinion in supportive and palliative care, 2018, Volume: 12, Issue:4 Topics: Activin Receptors, Type II; Activins; Anemia; Anemia, Aplastic; Blood Transfusion; Bone Marrow Diseases; Bone Marrow Failure Disorders; Hematinics; Hemoglobinuria, Paroxysmal; Humans; Immunoglobulin Fc Fragments; Quality of Life; Recombinant Fusion Proteins	2018
Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood, 2019, 02-21, Volume: 133, Issue:8 Topics: Activin Receptors, Type II; Activins; Anemia; Bone Morphogenetic Proteins; Disease-Free Survival; Erythrocyte Transfusion; Growth Differentiation Factors; Humans; Immunoglobulin Fc Fragments; Iron Overload; Myelodysplastic Syndromes; Recombinant Fusion Proteins; Survival Rate	2019
The ESA scenario gets complex: from biosimilar epoetins to activin traps. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2015, Volume: 30, Issue:4 Topics: Activins; Anemia; Biosimilar Pharmaceuticals; Erythropoietin; Hematinics; Humans	2015
Experimental and investigational therapies for chemotherapy-induced anemia. Expert opinion on investigational drugs, 2015, Volume: 24, Issue:11 Topics: Activins; Anemia; Animals; Antineoplastic Agents; Disease Progression; Drug Design; Drugs, Investigational; Hematinics; Hepcidins; Humans; Neoplasms	2015
New Treatment Approaches for the Anemia of CKD. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2016, Volume: 67, Issue:1 Topics: Activins; Anemia; Hematinics; Humans; Receptors, Erythropoietin; Renal Insufficiency, Chronic	2016
Ineffective erythropoiesis and regulation of iron status in iron loading anaemias. British journal of haematology, 2016, Volume: 172, Issue:4 Topics: Activins; Anemia; Animals; beta-Thalassemia; Erythropoiesis; Hematinics; Hepcidins; Humans; Iron; Iron Overload; Mice	2016

Trials

2 trial(s) available for activins and Anemia

Article	Year
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. The Lancet. Oncology, 2017, Volume: 18, Issue:10 Topics: Activin Receptors, Type II; Activins; Adult; Aged; Anemia; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Germany; Humans; Immunoglobulin Fc Fragments; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Prospective Studies; Recombinant Fusion Proteins; Risk Assessment; Severity of Illness Index; Survival Analysis; Time Factors; Treatment Outcome	2017
Diminished erythropoietin-induced erythroid growth in patients with renal anemia is restored by recombinant human erythroid differentiation factor. American journal of hematology, 1994, Volume: 47, Issue:3 Topics: Activins; Adolescent; Adult; Anemia; Cell Differentiation; Cells, Cultured; Dose-Response Relationship, Drug; Erythrocytes; Erythroid Precursor Cells; Erythropoiesis; Erythropoietin; Female; Humans; Inhibins; Interleukin-3; Kidney Failure, Chronic; Male; Middle Aged; Recombinant Proteins	1994

Article

Year

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.

The Lancet. Oncology, 2017, Volume: 18, Issue:10

Topics: Activin Receptors, Type II; Activins; Adult; Aged; Anemia; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Germany; Humans; Immunoglobulin Fc Fragments; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Prospective Studies; Recombinant Fusion Proteins; Risk Assessment; Severity of Illness Index; Survival Analysis; Time Factors; Treatment Outcome

2017

Diminished erythropoietin-induced erythroid growth in patients with renal anemia is restored by recombinant human erythroid differentiation factor.

American journal of hematology, 1994, Volume: 47, Issue:3

Topics: Activins; Adolescent; Adult; Anemia; Cell Differentiation; Cells, Cultured; Dose-Response Relationship, Drug; Erythrocytes; Erythroid Precursor Cells; Erythropoiesis; Erythropoietin; Female; Humans; Inhibins; Interleukin-3; Kidney Failure, Chronic; Male; Middle Aged; Recombinant Proteins

1994

Other Studies

1 other study(ies) available for activins and Anemia

Article	Year
In vivo treatment with erythroid differentiation factor (EDF/activin A) increases erythroid precursors (CFU-E and BFU-E) in mice. Biochemical and biophysical research communications, 1989, Dec-29, Volume: 165, Issue:3 Topics: Activins; Anemia; Animals; Bone Marrow Cells; Cell Differentiation; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Erythroid Precursor Cells; Erythropoiesis; Humans; Inhibins; Kinetics; Male; Mice; Mice, Inbred C3H; Recombinant Proteins; Spleen	1989

Article

Year

In vivo treatment with erythroid differentiation factor (EDF/activin A) increases erythroid precursors (CFU-E and BFU-E) in mice.

Biochemical and biophysical research communications, 1989, Dec-29, Volume: 165, Issue:3

Topics: Activins; Anemia; Animals; Bone Marrow Cells; Cell Differentiation; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Erythroid Precursor Cells; Erythropoiesis; Humans; Inhibins; Kinetics; Male; Mice; Mice, Inbred C3H; Recombinant Proteins; Spleen

1989